Hans LennernÃ¤s

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3151235/publications.pdf

Version: 2024-02-01

159 papers	15,207 citations	34076 52 h-index	18633 119 g-index
189 all docs	189 docs citations	189 times ranked	10994 citing authors

#	Article	IF	Citations
1	Oral Drug Delivery, Absorption and Bioavailability. , 2022, , 406-437.		3
2	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. European Journal of Pharmaceutical Sciences, 2022, 170, 106098.	1.9	29
3	Chemotherapeutics Combined with Luminal Irritants: Effects on Small-Intestinal Mannitol Permeability and Villus Length in Rats. International Journal of Molecular Sciences, 2022, 23, 1021.	1.8	6
4	Drug Resistance and Endoplasmic Reticulum Stress in Hepatocellular Carcinoma. Cells, 2022, 11, 632.	1.8	30
5	Protective Effects of Melatonin and Misoprostol against Experimentally Induced Increases in Intestinal Permeability in Rats. International Journal of Molecular Sciences, 2022, 23, 2912.	1.8	2
6	Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research. Pharmaceutics, 2022, 14, 801.	2.0	4
7	Drug diffusion in biomimetic hydrogels: importance for drug transport and delivery in non-vascular tumor tissue. European Journal of Pharmaceutical Sciences, 2022, 172, 106150.	1.9	3
8	Does the choice of applied physiologicallyâ€based pharmacokinetics platform matter? A case study on simvastatin disposition and drugâ€“drug interaction. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1194-1209.	1.3	5
9	Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies. Frontiers in Pharmacology, 2021, 12, 681417.	1.6	57
10	Anthracyclins Increase PUFAs: Potential Implications in ER Stress and Cell Death. Cells, 2021, 10, 1163.	1.8	10
11	In Vitro Cell Toxicity and Intracellular Uptake of Doxorubicin Exposed as a Solution or Liposomes: Implications for Treatment of Hepatocellular Carcinoma. Cells, 2021, 10, 1717.	1.8	25
12	Melatonin-Activated Receptor Signaling Pathways Mediate Protective Effects on Surfactant-Induced Increase in Jejunal Mucosal Permeability in Rats. International Journal of Molecular Sciences, 2021, 22, 10762.	1.8	4
13	Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2021, 22, 13051.	1.8	14
14	ICH M9 Guideline in Development on Biopharmaceutics Classification System-Based Biowaivers: An Industrial Perspective from the IQ Consortium. Molecular Pharmaceutics, 2020, 17, 361-372.	2.3	13
15	Prevention of Rat Intestinal Injury with a Drug Combination of Melatonin and Misoprostol. International Journal of Molecular Sciences, 2020, 21, 6771.	1.8	7
16	Pulmonary drug absorption and systemic exposure in human: Predictions using physiologically based biopharmaceutics modeling. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 191-202.	2.0	16
17	Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obesity Science and Practice, 2020, 6, 313-323.	1.0	18
18	The Critical Role of Passive Permeability in Designing Successful Drugs. ChemMedChem, 2020, 15, 1862-1874.	1.6	53

#	Article	IF	Citations
19	Drug Absorption Parameters Obtained Using the Isolated Perfused Rat Lung Model Are Predictive of Rat In Vivo Lung Absorption. AAPS Journal, 2020, 22, 71.	2.2	16
20	Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat. Pharmaceutics, 2020, 12, 242.	2.0	13
21	Antibody-Drug Conjugates and Targeted Treatment Strategies for Hepatocellular Carcinoma: A Drug-Delivery Perspective. Molecules, 2020, 25, 2861.	1.7	14
22	The In Vivo Effect of Transcellular Permeation Enhancers on the Intestinal Permeability of Two Peptide Drugs Enalaprilat and Hexarelin. Pharmaceutics, 2020, 12, 99.	2.0	15
23	Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations. Applied Sciences (Switzerland), 2020, 10, 2376.	1.3	13
24	Lipiodol-based emulsions used for transarterial chemoembolization and drug delivery: Effects of composition on stability and product quality. Journal of Drug Delivery Science and Technology, 2019, 53, 101143.	1.4	14
25	Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. Cancers, 2019, 11, 1024.	1.7	41
26	Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches. Pharmaceutics, 2019, 11, 411.	2.0	140
27	Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model. Molecular Pharmaceutics, 2019, 16, 3053-3064.	2.3	23
28	Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. Neurogastroenterology and Motility, 2019, 31, e13617.	1.6	46
29	Pulmonary absorption â€“ estimation of effective pulmonary permeability and tissue retention of ten drugs using an ex vivo rat model and computational analysis. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 124, 1-12.	2.0	31
30	Reply to â€œComment on â€˜In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinomaâ€™â€• Molecular Pharmaceutics, 2018, 15, 336-340.	2.3	1
31	Porcine and Human In Vivo Simulations for Doxorubicin-Containing Formulations Used in Locoregional Hepatocellular Carcinoma Treatment. AAPS Journal, 2018, 20, 96.	2.2	7
32	Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded â€˜21st Century BA/BEâ€™ project. International Journal of Pharmaceutics, 2018, 548, 120-127.	2.6	41
33	Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions. Drug Metabolism and Disposition, 2018, 46, 1420-1433.	1.7	23
34	A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition. Molecular Pharmaceutics, 2017, 14, 686-698.	2.3	21
35	In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma. Molecular Pharmaceutics, 2017, 14, 448-458.	2.3	30
36	Lipiodol does not affect the tissue distribution of intravenous doxorubicin infusion in pigs. Journal of Pharmacy and Pharmacology, 2017, 69, 135-142.	1.2	6

#	Article	IF	Citations
37	Regional Intestinal Permeability in Rats: A Comparison of Methods. Molecular Pharmaceutics, 2017, 14, 4252-4261.	2.3	37
38	Preclinical Effect of Absorption Modifying Excipients on Rat Intestinal Transport of Model Compounds and the Mucosal Barrier Marker ⁵¹Cr-EDTA. Molecular Pharmaceutics, 2017, 14, 4243-4251.	2.3	34
39	In Vivo Mechanisms of Intestinal Drug Absorption from Aprepitant Nanoformulations. Molecular Pharmaceutics, 2017, 14, 4233-4242.	2.3	49
40	An Intraprostatic Modified Release Formulation of Antiandrogen 2-Hydroxyflutamide for Localized Prostate Cancer. Journal of Urology, 2017, 198, 1333-1339.	0.2	7
41	Optimization of the Ussing chamber setup with excised rat intestinal segments for dissolution/permeation experiments of poorly soluble drugs. Drug Development and Industrial Pharmacy, 2017, 43, 338-346.	0.9	10
42	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results. European Journal of Pharmaceutical Sciences, 2017, 96, 610-625.	1.9	58
43	IMI â€“ oral biopharmaceutics tools project â€“ evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds. European Journal of Pharmaceutical Sciences, 2017, 96, 598-609.	1.9	34
44	IMI â€“ Oral biopharmaceutics tools project â€“ Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes. European Journal of Pharmaceutical Sciences, 2017, 96, 626-642.	1.9	41
45	InÂVitro Release Mechanisms of Doxorubicin From a Clinical Bead Drug-Delivery System. Journal of Pharmaceutical Sciences, 2016, 105, 3387-3398.	1.6	37
46	Regional Intestinal Permeability of Three Model Drugs in Human. Molecular Pharmaceutics, 2016, 13, 3013-3021.	2.3	57
47	Regional Intestinal Permeability in Dogs: Biopharmaceutical Aspects for Development of Oral Modified-Release Dosage Forms. Molecular Pharmaceutics, 2016, 13, 3022-3033.	2.3	32
48	Translating Human Effective Jejunal Intestinal Permeability to Surface-Dependent Intrinsic Permeability: a Pragmatic Method for a More Mechanistic Prediction of Regional Oral Drug Absorption. AAPS Journal, 2015, 17, 1177-1192.	2.2	20
49	Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. Molecular Pharmaceutics, 2015, 12, 4166-4173.	2.3	17
50	Human in Vivo Regional Intestinal Permeability: Quantitation Using Site-Specific Drug Absorption Data. Molecular Pharmaceutics, 2015, 12, 2026-2039.	2.3	52
51	Direct In Vivo Human Intestinal Permeability (Peff) Determined with Different Clinical Perfusion and Intubation Methods. Journal of Pharmaceutical Sciences, 2015, 104, 2702-2726.	1.6	83
52	Treatment of intermediate stage hepatocellular carcinoma: a review of intrahepatic doxorubicin drug-delivery systems. Therapeutic Delivery, 2014, 5, 447-466.	1.2	30
53	High-resolution mass spectrometric investigation of the phase I and II metabolites of finasteride in pig plasma, urine and bile. Xenobiotica, 2014, 44, 498-510.	0.5	2
54	Effects of verapamil on the pharmacokinetics and hepatobiliary disposition of fexofenadine in pigs. European Journal of Pharmaceutical Sciences, 2014, 57, 214-223.	1.9	5

#	Article	IF	Citations
55	Oral biopharmaceutics-current status and identified gaps of understanding. European Journal of Pharmaceutical Sciences, 2014, 57, 98.	1.9	3
56	Regional intestinal drug permeation: Biopharmaceutics and drug development. European Journal of Pharmaceutical Sciences, 2014, 57, 333-341.	1.9	77
57	In vivo methods for drug absorption â€“ Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences, 2014, 57, 99-151.	1.9	226
58	Evaluation of the use of Classical Nucleation Theory for predicting intestinal crystalline precipitation of two weakly basic BSC class II drugs. European Journal of Pharmaceutical Sciences, 2014, 53, 17-27.	1.9	21
59	The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance. Journal of Pharmaceutical Sciences, 2014, 103, 3377-3397.	1.6	60
60	The Effects of Lipiodol and Cyclosporin A on the Hepatobiliary Disposition of Doxorubicin in Pigs. Molecular Pharmaceutics, 2014, 11, 1301-1313.	2.3	9
61	Human in Vivo Regional Intestinal Permeability: Importance for Pharmaceutical Drug Development. Molecular Pharmaceutics, 2014, 11, 12-23.	2.3	69
62	Pharmacokinetics of an Injectable Modified-Release 2-Hydroxyflutamide Formulation in the Human Prostate Gland Using a Semiphysiologically Based Biopharmaceutical Model. Molecular Pharmaceutics, 2014, 11, 3097-3111.	2.3	19
63	Investigation of Hepatobiliary Disposition of Doxorubicin Following Intrahepatic Delivery of Different Dosage Forms. Molecular Pharmaceutics, 2014, 11, 131-144.	2.3	23
64	Passive Lipoidal Diffusion and Carrier-Mediated Cell Uptake Are Both Important Mechanisms of Membrane Permeation in Drug Disposition. Molecular Pharmaceutics, 2014, 11, 1727-1738.	2.3	106
65	Combined in Vitroâ€“in Vivo Approach To Assess the Hepatobiliary Disposition of a Novel Oral Thrombin Inhibitor. Molecular Pharmaceutics, 2013, 10, 4252-4262.	2.3	14
66	In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: Application of the mechanistic absorption model GI-Sim. European Journal of Pharmaceutical Sciences, 2013, 49, 679-698.	1.9	141
67	Extensive intestinal glucuronidation of raloxifenein vivoin pigs and impact for oral drug delivery. Xenobiotica, 2012, 42, 917-928.	0.5	12
68	Binding Processes Determine the Stereoselective Intestinal and Hepatic Extraction of Verapamil in Vivo. Molecular Pharmaceutics, 2012, 9, 3034-3045.	2.3	5
69	The Fraction Dose Absorbed, in Humans, and High Jejunal Human Permeability Relationship. Molecular Pharmaceutics, 2012, 9, 1847-1851.	2.3	74
70	In Vivo Dog Intestinal Precipitation of Mebendazole: A Basic BCS Class II Drug. Molecular Pharmaceutics, 2012, 9, 2903-2911.	2.3	42
71	The Pharmacokinetics and Hepatic Disposition of Repaglinide in Pigs: Mechanistic Modeling of Metabolism and Transport. Molecular Pharmaceutics, 2012, 9, 823-841.	2.3	24
72	Biliary Excretion of Ximelagatran and Its Metabolites and the Influence of Erythromycin Following Intraintestinal Administration to Healthy Volunteers. Journal of Clinical Pharmacology, 2011, 51, 770-783.	1.0	4

#	Article	IF	Citations
73	Human Jejunal Effective Permeability and Its Correlation with Preclinical Drug Absorption Models. Journal of Pharmacy and Pharmacology, 2011, 49, 627-638.	1.2	172
74	A Residence-Time Distribution Analysis of the Hydrodynamics within the Intestine in Man during a Regional Single-pass Perfusion with Loc-I-Gut: In-vivo Permeability Estimation. Journal of Pharmacy and Pharmacology, 2011, 49, 682-686.	1.2	40
75	Regional Intestinal Permeability in Rats of Compounds with Different Physicochemical Properties and Transport Mechanisms. Journal of Pharmacy and Pharmacology, 2011, 49, 687-690.	1.2	84
76	Water-soluble Î²-Cyclodextnns in Paediatnc Oral Solutions of Spironolactone: Preclinical Evaluation of Spironolactone Bioavailability from Solutions of Î²-Cyclodextrin Derivatives in Rats. Journal of Pharmacy and Pharmacology, 2011, 50, 611-619.	1.2	34
77	Concentration- and Region-dependent Intestinal Permeability of Fluvastatin in the Rat. Journal of Pharmacy and Pharmacology, 2011, 50, 737-744.	1.2	25
78	Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. European Journal of Pharmaceutical Sciences, 2011, 43, 89-98.	1.9	49
79	The BCS, BDDCS, and Regulatory Guidances. Pharmaceutical Research, 2011, 28, 1774-1778.	1.7	77
80	Effects of Ketoconazole on the In Vivo Biotransformation and Hepatobiliary Transport of the Thrombin Inhibitor AZD0837 in Pigs. Drug Metabolism and Disposition, 2011, 39, 239-246.	1.7	7
81	In Vivo Investigation in Pigs of Intestinal Absorption, Hepatobiliary Disposition, and Metabolism of the 5Î±-Reductase Inhibitor Finasteride and the Effects of Coadministered Ketoconazole. Drug Metabolism and Disposition, 2011, 39, 847-857.	1.7	15
82	Effects of cholesterol and model transmembrane proteins on drug partitioning into lipid bilayers as analysed by immobilized-liposome chromatography. Journal of Pharmacy and Pharmacology, 2010, 53, 1477-1487.	1.2	26
83	Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine. Journal of Pharmacy and Pharmacology, 2010, 55, 963-972.	1.2	27
84	Intestinal drug absorption and bioavailability: beyond involvement of single transport function. Journal of Pharmacy and Pharmacology, 2010, 55, 429-433.	1.2	26
85	The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extensionâ€. Journal of Pharmacy and Pharmacology, 2010, 57, 273-285.	1.2	169
86	Hepatic Disposition of Ximelagatran and Its Metabolites in Pig; Prediction of the Impact of Membrane Transporters Through a Simple Disposition Model. Pharmaceutical Research, 2010, 27, 597-607.	1.7	3
87	Gastrointestinal metabolism of a vegetable-oil emulsion in healthy subjects. American Journal of Clinical Nutrition, 2010, 92, 515-524.	2.2	29
88	Effect of a Single Gemfibrozil Dose on the Pharmacokinetics of Rosuvastatin in Bile and Plasma in Healthy Volunteers. Journal of Clinical Pharmacology, 2010, 50, 1039-1049.	1.0	17
89	High-Permeability Criterion for BCS Classification: Segmental/pH Dependent Permeability Considerations. Molecular Pharmaceutics, 2010, 7, 1827-1834.	2.3	94
90	The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CL_{int}), Maximum Velocity of the Metabolic Reaction (V_{max}), and Michaelis Constant (K_m): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations. Drug Metabolism and Disposition, 2009, 37, 47-58.	1.7	38

#	Article	IF	Citations
91	Different Effects of Ketoconazole on the Stereoselective First-Pass Metabolism of R/S-Verapamil in the Intestine and the Liver: Important for the Mechanistic Understanding of First-Pass Drug-Drug Interactions. Drug Metabolism and Disposition, 2009, 37, 2186-2196.	1.7	16
92	Identification of Finasteride Metabolites in Human Bile and Urine by High-Performance Liquid Chromatography/Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2009, 37, 2008-2017.	1.7	17
93	Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. European Journal of Endocrinology, 2009, 161, 119-130.	1.9	151
94	The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. European Journal of Pharmaceutical Sciences, 2009, 36, 433-443.	1.9	38
95	Online capillary solid phase extraction and liquid chromatographic separation with quantitative tandem mass spectrometric detection (SPE-LCâ€“MS/MS) of ximelagatran and its metabolites in a complex matrix. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 291-297.	1.2	7
96	Toward an Increased Understanding of the Barriers to Colonic Drug Absorption in Humans: Implications for Early Controlled Release Candidate Assessment. Molecular Pharmaceutics, 2009, 6, 60-73.	2.3	114
97	Ethanolâ^'Drug Absorption Interaction: Potential for a Significant Effect on the Plasma Pharmacokinetics of Ethanol Vulnerable Formulations. Molecular Pharmaceutics, 2009, 6, 1429-1440.	2.3	47
98	Enterohepatic Disposition of Rosuvastatin in Pigs and the Impact of Concomitant Dosing with Cyclosporine and Gemfibrozil. Drug Metabolism and Disposition, 2009, 37, 2349-2358.	1.7	27
99	The Use of BDDCS in Classifying the Permeability of Marketed Drugs. Pharmaceutical Research, 2008, 25, 483-488.	1.7	124
100	Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 749-758.	1.5	21
101	Intestinal and Hepatobiliary Transport of Ximelagatran and Its Metabolites in Pigs. Drug Metabolism and Disposition, 2008, 36, 1519-1528.	1.7	19
102	Modeling Gastrointestinal Drug Absorption Requires More In Vivo Biopharmaceutical Data: Experience from In Vivo Dissolution and Permeability Studies in Humans. Current Drug Metabolism, 2007, 8, 645-657.	0.7	84
103	Simultaneous assessment of lipid classes and bile acids in human intestinal fluid by solid-phase extraction and HPLC methods. Journal of Lipid Research, 2007, 48, 242-251.	2.0	47
104	Pharmacokinetics of gefitinib in humans: The influence of gastrointestinal factors. International Journal of Pharmaceutics, 2007, 341, 134-142.	2.6	58
105	Animal data: The contributions of the Ussing Chamber and perfusion systems to predicting human oral drug delivery in vivoâ^†. Advanced Drug Delivery Reviews, 2007, 59, 1103-1120.	6.6	128
106	Presentation of a Structurally Diverse and Commercially Available Drug Data Set for Correlation and Benchmarking Studies. Journal of Medicinal Chemistry, 2006, 49, 6660-6671.	2.9	48
107	Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model. Pharmaceutical Research, 2006, 23, 1675-1686.	1.7	344
108	A Clinical Single-Pass Perfusion Investigation of the Dynamic in Vivo Secretory Response to a Dietary Meal in Human Proximal Small Intestine. Pharmaceutical Research, 2006, 23, 742-751.	1.7	66

#	Article	IF	Citations
109	Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. European Journal of Pharmaceutical Sciences, 2006, 29, 205-214.	1.9	55
110	FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL. Drug Metabolism and Disposition, 2006, 34, 1182-1189.	1.7	39
111	The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids. Pharmaceutical Research, 2005, 22, 2141-2151.	1.7	244
112	Transport Characteristics of Fexofenadine in the Caco-2 Cell Model. Pharmaceutical Research, 2004, 21, 1398-1404.	1.7	116
113	Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatographyâ€“tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 804, 303-311.	1.2	23
114	St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism*1. Clinical Pharmacology and Therapeutics, 2004, 75, 298-309.	2.3	118
115	Intestinal and bloodâ€“brain drug transport: beyond involvement of a single transport function. Drug Discovery Today: Technologies, 2004, 1, 417-422.	4.0	12
116	Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification. Molecular Pharmaceutics, 2004, 1, 85-96.	2.3	691
117	Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. European Journal of Pharmaceutical Sciences, 2004, 21, 553-560.	1.9	71
118	St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism*1. Clinical Pharmacology and Therapeutics, 2004, 75, 298-309.	2.3	2
119	Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. European Journal of Pharmaceutical Sciences, 2003, 19, 57-65.	1.9	19
120	Pulmonary Absorption Rate and Bioavailability of Drugs in Vivo in Rats: Structureâ€“Absorption Relationships and Physicochemical Profiling of Inhaled Drugs. Journal of Pharmaceutical Sciences, 2003, 92, 1216-1233.	1.6	130
121	Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine,. Clinical Pharmacology and Therapeutics, 2003, 74, 423-436.	2.3	81
122	The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. British Journal of Clinical Pharmacology, 2003, 55, 182-190.	1.1	70
123	Clinical Pharmacokinetics of Atorvastatin. Clinical Pharmacokinetics, 2003, 42, 1141-1160.	1.6	482
124	ABSORPTION/METABOLISM OF SULFORAPHANE AND QUERCETIN, AND REGULATION OF PHASE II ENZYMES, IN HUMAN JEJUNUM IN VIVO. Drug Metabolism and Disposition, 2003, 31, 805-813.	1.7	199
125	Drug Absorption from the Isolated Perfused Rat Lungâ€“Correlations with Drug Physicochemical Properties and Epithelial Permeability. Journal of Drug Targeting, 2003, 11, 61-74.	2.1	91
126	Chemotherapy and Antiangiogenesis. Acta OncolÃ³gica, 2003, 42, 294-303.	0.8	60

#	Article	IF	Citations
127	Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release Tablets. Clinical Neuropharmacology, 2003, 26, 156-163.	0.2	206
128	Miniaturized Nebulization Catheters: A New Approach for Delivery of Defined Aerosol Doses to the Rat Lung. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 283-296.	1.2	41
129	High airway-to-blood transport of an opioid tetrapeptide in the isolated rat lung after aerosol delivery. Peptides, 2002, 23, 469-478.	1.2	24
130	Regional differences in bioavailability of an opioid tetrapeptide in vivo in rats after administration to the respiratory tract. Peptides, 2002, 23, 479-488.	1.2	15
131	Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharmaceutical Research, 2002, 19, 1400-1416.	1.7	362
132	Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharmaceutical Research, 2001, 18, 742-744.	1.7	54
133	Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-GutÂ®) in humans. European Journal of Pharmaceutical Sciences, 2001, 12, 239-250.	1.9	35
134	Dissolution of hydrocortisone in human and simulated intestinal fluids. Pharmaceutical Research, 2000, 17, 183-189.	1.7	74
135	No evidence for the involvement of the multidrug resistance-associated protein and/or the monocarboxylic acid transporter in the intestinal transport of fluvastatin in rats. AAPS PharmSci, 2000, 2, 62-68.	1.3	11
136	SPR Biosensor Studies of the Direct Interaction between 27 Drugs and a Liposome Surface:Â Correlation with Fraction Absorbed in Humans. Journal of Medicinal Chemistry, 2000, 43, 2083-2086.	2.9	133
137	The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. British Journal of Clinical Pharmacology, 1999, 48, 180-189.	1.1	74
138	Surface activity and concentration dependent intestinal permeability in the rat. Pharmaceutical Research, 1999, 16, 97-102.	1.7	14
139	A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. European Journal of Pharmaceutical Sciences, 1999, 8, 19-27.	1.9	36
140	Jejunal absorption and metabolism of R/S-verapamil in humans. Pharmaceutical Research, 1998, 15, 856-862.	1.7	95
141	Correlation of Human Jejunal Permeability (in Vivo) of Drugs with Experimentally and Theoretically Derived Parameters. A Multivariate Data Analysis Approach. Journal of Medicinal Chemistry, 1998, 41, 4939-4949.	2.9	420
142	Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors. Clinical Pharmacokinetics, 1997, 32, 403-425.	1.6	447
143	Characterization of fluids from the stomach and proximal jejunum in men and women. Pharmaceutical Research, 1997, 14, 497-502.	1.7	345
144	Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharmaceutical Research, 1997, 14, 1127-1132.	1.7	53

#	Article	IF	Citations
145	Rat jejunal permeability and metabolism of mu-selective tetrapeptides in gastrointestinal fluids from humans and rats. Pharmaceutical Research, 1997, 14, 1780-1785.	1.7	28
146	A new approach for direct in vivo dissolution studies of poorly soluble drugs. Pharmaceutical Research, 1997, 14, 1490-1492.	1.7	24
147	Is the jejunal permeability in rats age-dependent?. Pharmaceutical Research, 1997, 14, 1278-1281.	1.7	15
148	Comparison between permeability coefficients in rat and human jejunum. Pharmaceutical Research, 1996, 13, 1336-1342.	1.7	385
149	Jejunal permeability and hepatic extraction of fluvastatin in humans. Clinical Pharmacology and Therapeutics, 1996, 60, 493-503.	2.3	76
150	Permeability and clearance views of drug absorption: A commentary. Journal of Pharmacokinetics and Pharmacodynamics, 1995, 23, 333-337.	0.6	20
151	A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical Research, 1995, 12, 413-420.	1.7	4,287
152	Regional rectal perfusion: a new in vivo approach to study rectal drug absorption in man. Pharmaceutical Research, 1995, 12, 426-432.	1.7	97
153	Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?. Pharmaceutical Research, 1995, 12, 1573-1582.	1.7	94
154	The Lack of Effect of Induced Net Fluid Absorption on thein vivoPermeability of Terbutaline in the Human Jejunum. Journal of Drug Targeting, 1995, 3, 191-200.	2.1	45
155	Experimental estimation of the effective unstirred water layer thickness in the human jejunum, and its importance in oral drug absorption. European Journal of Pharmaceutical Sciences, 1995, 3, 247-253.	1.9	92
156	The influence of net water absorption on the permeability of antipyrine and levodopa in the human jejunum. Pharmaceutical Research, 1994, 11, 1540-1544.	1.7	43
157	Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat. Pharmaceutical Research, 1993, 10, 727-731.	1.7	38
158	Regional gastrointestinal absorption of the beta-blocker pafenolol in the rat and intestinal transit rate determined by movement of 14C-polyethylene glycol (PEG) 4000. Pharmaceutical Research, 1993, 10, 130-135.	1.7	36
159	Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharmaceutical Research, 1992, 09, 1243-1251.	1.7	191